Literature DB >> 21504498

CIDP - the relevance of recent advances in Schwann cell/axonal neurobiology.

John D Pollard1, Patricia J Armati.   

Abstract

Early pathological studies in patients with acute and chronic inflammatory demyelinating neuropathies, and the animal model experimental autoimmune neuritis (EAN) showed similarities in the process of demyelination. These studies focused on compact myelin proteins and peptides as targets of immune attack in Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and EAN. However, serological studies in patients with subsets of GBS highlighted the importance of gangliosides - glycolipids enriched in non-compact Schwann cell regions and the node, paranodal, and internodal axolemma. In the acute motor axonal neuropathy (AMAN) rabbit model, antibodies to the ganglioside GM1 bind in the nodal region, impair Na channel clustering and disturb Schwann cell/axon organisation. Schwann cell neurobiological studies now highlight the importance of adhesion molecules, including neurofascins, gliomedin, contactins, and NrCAM to Schwann cell/axon integrity. Changes to nodal fine structure by immune responses against such molecules may provide a mechanism for reversible conduction failure or block. Recovery of patients with CIDP or multifocal motor neuropathy (MMN) following treatment may sometimes be better explained by reversal of conduction failure than remyelination or regeneration. This review considers the importance of the intricate molecular arrangements at the nodal and paranodal regions in inflammatory neuropathies such as CIDP. Early images of compact myelin stripping and phagocytosis, may have diverted the research focus away from these vital non-compact myelin Schwann cell areas.
© 2011 Peripheral Nerve Society.

Entities:  

Mesh:

Year:  2011        PMID: 21504498     DOI: 10.1111/j.1529-8027.2011.00323.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  18 in total

Review 1.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

2.  Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy.

Authors:  Jia-Ying Sung; Jowy Tani; Susanna B Park; Matthew C Kiernan; Cindy Shin-Yi Lin
Journal:  Brain       Date:  2014-06-19       Impact factor: 13.501

3.  Effective dosing strategies for therapeutic immunoglobulin: managing wear-off effects in antibody replacement to immunomodulation.

Authors:  S A Misbah
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Optimizing immunoglobulin G therapy in chronic autoimmune neuropathies.

Authors:  M Berger
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

5.  Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.

Authors:  Gisa Ellrichmann; Ralf Gold; Ilya Ayzenberg; Min-Suk Yoon; Christiane Schneider-Gold
Journal:  Ther Adv Neurol Disord       Date:  2016-12-09       Impact factor: 6.570

Review 6.  Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Authors:  Verena I Leussink; Hans-Peter Hartung; Bernd C Kieseier; Mark Stettner
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

7.  Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.

Authors:  Luis Querol; Gisela Nogales-Gadea; Ricardo Rojas-Garcia; Jordi Diaz-Manera; Julio Pardo; Angel Ortega-Moreno; Maria Jose Sedano; Eduard Gallardo; Jose Berciano; Rafael Blesa; Josep Dalmau; Isabel Illa
Journal:  Neurology       Date:  2014-02-12       Impact factor: 9.910

8.  An idiopathic thrombocytopenic purpura with polyneuropathy.

Authors:  Valeria Katchan; Paula David; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

9.  Erythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathy.

Authors:  Gang Zhang; Helmar C Lehmann; Nataliia Bogdanova; Tong Gao; Jiangyang Zhang; Kazim A Sheikh
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

Review 10.  Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.

Authors:  Melvin Berger; Jeffrey A Allen
Journal:  Muscle Nerve       Date:  2015-01-29       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.